Michael Sofia

Co-founder and Chief Scientific Officer of Arbutus Biopharma, Inc.

Country: USA

Michael J. Sofia, Ph.D. is Co-founder and Chief Scientific Officer of Arbutus Biopharma, Inc. a company focused on therapies to cure hepatitis B and coronaviruses. He has introduced numerous drugs into clinical development for the treatment of infectious diseases and inflammatory diseases and is the principle inventor of sofosbuvir currently marketed as the backbone of HCV curative therapies Sovaldi, Harvoni, Epclusa and Vosevi. Mike has received numerous awards including the 2015 Economist Innovation Award, the 2016 IUPAC-Richter Prize, the 2016 Lasker-Debakey Award in Clinical Medical Research, the 2017 Gertrude Elion Award, and the 2020 Cameron Prize for Therapeutics.